Alnylam Pharmaceuticals (ALNY) Net Income towards Common Stockholders (2009 - 2026)

Alnylam Pharmaceuticals has reported Net Income towards Common Stockholders for 18 years, with the latest figure at $206.0 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders rose 1228.66% year-over-year to $206.0 million; the trailing twelve-month figure through Mar 2026 stood at $543.9 million (up 336.01% YoY), and the FY2025 full-year result was $313.7 million, up 212.79% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at $206.0 million, up from $111.5 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $292.7 million in Q3 2025, with the low at -$405.9 million in Q3 2022.
• Historically, Net Income towards Common Stockholders has averaged -$77.9 million across 5 years, with a median of -$83.8 million in 2024.
• Annual changes were most pronounced in 2025 — Net Income towards Common Stockholders tumbled 292.43% — and 2026, when it soared 1228.66%.
• Alnylam Pharmaceuticals' Net Income towards Common Stockholders stood at -$207.5 million in 2022, then soared by 33.55% to -$137.9 million in 2023, then soared by 39.24% to -$83.8 million in 2024, then jumped by 233.17% to $111.5 million in 2025, then jumped by 84.67% to $206.0 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at $206.0 million (Q1 2026), $111.5 million (Q4 2025), and $292.7 million (Q3 2025), per Business Quant data.